Products
Platform
Research
Market
Learn
IPO
Compare Baroda BNP Paribas Health and Wellness Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 2.28 | 1.86 |
NAV | ₹9.56 | ₹40.22 |
Fund Started | 09 Jun 2025 | 25 Jun 2018 |
Fund Size | ₹621.16 Cr | ₹6437.36 Cr |
Exit Load | Exit Load for units in excess of 10% of the investment,1% will be charged for redemption within 1 year. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹500
₹100
Expense Ratio
2.28
1.86
NAV
₹9.56
₹40.22
Fund Started
09 Jun 2025
25 Jun 2018
Fund Size
₹621.16 Cr
₹6437.36 Cr
Exit Load
Exit Load for units in excess of 10% of the investment,1% will be charged for redemption within 1 year.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | - | 3.31% |
3 Year | - | 26.49% |
5 Year | - | 18.90% |
1 Year
-
3.31%
3 Year
-
26.49%
5 Year
-
18.90%
Holding Analysis
Equity | 95.53% | 97.10% |
Cash | -0.26% | 2.90% |
Equity
95.53%
97.10%
Cash
-0.26%
2.90%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 9.25% |
Mankind Pharma Ltd. | 7.29% |
Divi's Laboratories Ltd. | 7.05% |
Apollo Hospitals Enterprise Ltd. | 6.18% |
Max Healthcare Institute Ltd. | 5.54% |
Cipla Ltd. | 5.38% |
Aster DM Healthcare Ltd. | 4.91% |
Abbott India Ltd. | 4.57% |
Astrazeneca Pharma India Ltd. | 4.00% |
Gland Pharma Ltd. | 3.73% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.88% |
Dr. Reddy's Laboratories Ltd. | 9.42% |
Divi's Laboratories Ltd. | 8.50% |
Aurobindo Pharma Ltd. | 7.62% |
Cipla Ltd. | 6.61% |
Lupin Ltd. | 5.40% |
Alkem Laboratories Ltd. | 3.98% |
Biocon Ltd. | 3.28% |
Mankind Pharma Ltd. | 2.79% |
Zydus Lifesciences Ltd. | 2.67% |
Fund Manager
Name | Sanjay Chawla | Dharmesh Kakkad |
Start Date | 09 Jun 2025 | 23 Feb 2021 |
Name
Sanjay Chawla
Dharmesh Kakkad
Start Date
09 Jun 2025
23 Feb 2021
About Fund
Description | The scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 09 Jun 2025 | 25 Jun 2018 |
Description
The scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
09 Jun 2025
25 Jun 2018